US OptionsDetailed Quotes
NRXP240920C5000
- 0.10
- +0.05+100.00%
15min DelayClose Aug 23 16:00 ET
0.10High0.05Low
0.05Open0.05Pre Close9 Volume283 Open Interest5.00Strike Price70.00Turnover237.05%IV145.19%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1433Delta0.1720Gamma27.73Leverage Ratio-0.0057Theta0.0002Rho3.97Eff Leverage0.0013Vega
NRX Pharmaceuticals Stock Discussion
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
NRx Pharmaceuticals (NASDAQ:NRXP) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Secured $10.8-$16.3 million in convertible-debt funding to support FDA New Drug Applications for NRX-100(ketamine) and NRX-101.
2. Plans to file NDAs for NRX-100 in suicidal depression and NRX-101 for Acceler...
Set ready
Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Alignment With FDA on Pediatric Study Plan for NRX-100 (Ketamine)
loading zone
NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
No comment yet